Zenas zips up $118M to launch phase 3 for rare autoimmune disease candidate

Zenas BioPharma has raised a $118 million series B to zoom in on a pipeline of immune-based therapies and launch a phase 3 for its lead candidate that was licensed from Xencor less than a year ago.